Biocept Launches its c-MET Biomarker

Molecular oncology diagnostics company, Biocept, Inc., is expanding its cancer diagnostic portfolio with the launch of a new liquid biopsy detection test.

The company announced the launch of its c-MET amplification detection test utilizing a blood-based “liquid biopsy.” According to the company, the diagnostic assay can potentially help physicians identify which patients may be receptive to certain gastric and non-small cell lung cancer (NSCLC).

The c-MET signaling pathway has shown to be dysfunctional in a wide range of cancers. The company said that when this is the case, c-MET stimulates cell growth, invasion and metastasis – encouraging cells to resist timely death. Based on the role of the c-MET pathway in the proliferation of cancer cells, it is a target for many cancer drugs that are currently being developed.

Preliminary results from a Massachusetts General Hospital-led study showed that a novel small-molecule c-MET inhibitor showed promise in the treatment of c-MET amplified GI cancers. Preliminary results were presented at the 2015 Gastrointestinal Cancers Symposium (GICS). In addition to targeting this mechanism in GI cancers, c-MET abnormalities, along with T790M mutations, are recognized as common mechanisms of acquired resistance to epidermal growth factor tyrosine kinase inhibitors (EGFR TKIs) in advanced NSCLC. In January, Biocept launched an assay to detect T790M mutation in patients with NSCLC.

“It has been demonstrated that high levels of c-MET correlate with poor prognosis in several tumor types, including breast, ovarian, gastric and lung cancer among others,” said Veena Singh, MD, SVP and Senior Medical Director of Biocept. “Now the excitement around c-MET is focused on its potential as a biomarker that will be a companion diagnostic for targeted therapies in gastric and lung cancers.”

Biocept has developed proprietary technology platforms for detection of mutations that will assist physicians with important prognostic and predictive information to enhance individual treatment for cancer patients. Currently, the company offers its OncoCEE-GA test for gastric cancers, OncoCEE-BR test for breast cancer and OncoCEE-LU test for NSCLC. The company also plans to introduce CLIA validated tests for colorectal, prostate and other solid tumors based on its proprietary technology platforms over the next few months.

“The launch of our c-MET assay is consistent with our efforts to dedicate Biocept to transforming the field of personalized medicine,” said Raaj Trivedi, VP of Commercial Operations for Biocept. “As new targets like c-MET grow in their potential as companion diagnostics, obtaining tissue samples to detect the mutation will be challenging for cancers like lung and gastric. Biocept’s blood-based approach to oncology diagnostics avoids patient re-biopsy, allowing for molecular profiling and monitoring of patients with alterations in this key pathway throughout the course of therapy.”

Source: Biocept, Inc.

Last updated: 5/4/15; 9:50am EST

Check Also

FDA Approves Gavreto for the Treatment of Adults with Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer

SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: …

Leave a Reply

Your email address will not be published.